Comparative Pharmacology
Head-to-head clinical analysis: ENPRESSE 21 versus NORINYL 1 80 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENPRESSE 21 versus NORINYL 1 80 21 DAY.
ENPRESSE-21 vs NORINYL 1+80 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; suppresses gonadotropin release via estrogen-progestin negative feedback, preventing ovulation; alters cervical mucus and endometrial lining to inhibit sperm penetration and implantation.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
ENPRESSE-21 (ethinyl estradiol/norethindrone acetate) is an oral contraceptive. One tablet (0.035 mg ethinyl estradiol/0.5 mg norethindrone acetate) by mouth once daily for 21 days, followed by 7 placebo days.
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
None Documented
None Documented
Terminal elimination half-life is 8-10 hours; this supports once-daily dosing and reaches steady state within 2-3 days.
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Renal excretion of unchanged drug accounts for approximately 30-40% of the dose; hepatic metabolism accounts for the remainder, with metabolites eliminated in bile and feces.
Renal (40-60% as metabolites), fecal (20-30%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive